Bausch Health Companies Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Bausch Health Companies Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Bausch Health Companies Inc. zu Deinem Portfolio hinzuzufügen.
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appearance while enhancing natural beauty. LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aest...
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m.
Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.
Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, improved profitability, and management's commitment to debt reduction and strategic portfolio development. Despite a heavy debt load, refinancing progress and upgraded 2025 guidance support my thesis o...
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced ...
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, and CUPERTINO, Calif. , Sept. 11, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced t...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.